OncoMatch/Clinical Trials/NCT05775159
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Is NCT05775159 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for hepatocellular carcinoma.
Treatment: Volrustomig · Bevacizumab · Lenvatinib · Rilvegostomig · Gemcitabine · Cisplatin — GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Hepatocellular Carcinoma
Cholangiocarcinoma
Prior therapy
Cannot have received:
Previous treatment in the present study.
Lab requirements
Blood counts
Adequate organ and bone marrow function.
Kidney function
Adequate organ and bone marrow function.
Liver function
Adequate organ and bone marrow function.
Adequate organ and bone marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Birmingham, Alabama
- Research Site · Costa Mesa, California
- Research Site · Los Angeles, California
- Research Site · Orange, California
- Research Site · Miami Beach, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05775159 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify